Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**4-methylaminorex** is a synthetic stimulant drug of the 2-amino-5-aryloxazoline class, first synthesized in 1960 by McNeil Laboratories as a potential appetite suppressant. It acts primarily as an indirect sympathomimetic agent, stimulating the release of dopamine and norepinephrine, and to a lesser extent serotonin, by interacting with monoamine transporters. This results in increased alertness, euphoria, cognitive enhancement, and reinforcing properties similar to amphetamines and cocaine but with a longer duration of action. The drug exists as four stereoisomers (cis and trans forms), with varying potency; the trans-(4S,5S) isomer is most potent. Although initially investigated for medical use (notably appetite suppression), its development was discontinued in favor of aminorex due to safety concerns. Today it is classified as a Schedule I substance in many countries due to its abuse potential[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-methylaminorex.